Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Here's why Pfizer is revising its revenue forecasts
07:47am, Tuesday, 16'th Dec 2025
The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.
First Look: Ford EV pivot, AI infra slump, Uber suit
07:38am, Tuesday, 16'th Dec 2025
Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric
Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.
07:25am, Tuesday, 16'th Dec 2025
Pfizer expects revenue and earnings to fall in 2026.
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings
07:16am, Tuesday, 16'th Dec 2025
Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a
Pfizer shares fall after it forecasts 2026 revenue below estimates
07:14am, Tuesday, 16'th Dec 2025
Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of...
Nasdaq drops back as Wall Street digests slowing jobs data, retail sales
07:08am, Tuesday, 16'th Dec 2025
12:05pm: Pfizer cuts revenue targets Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly...
Pfizer Adds to Its Big Bet on Weight Loss Drugs
07:03am, Tuesday, 16'th Dec 2025
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included al
Pfizer forecasts 2026 profit below expectations on lower COVID product sales
06:54am, Tuesday, 16'th Dec 2025
Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading.
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
06:45am, Tuesday, 16'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other compone
Capital Asset Advisory Services LLC Has $2.79 Million Stock Holdings in Pfizer Inc. $PFE
06:16am, Tuesday, 16'th Dec 2025
Capital Asset Advisory Services LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 51.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission
Pfizer (NYSE:PFE) Stock Price Up 2.3% Following Dividend Announcement
01:30am, Tuesday, 16'th Dec 2025
Shares of Pfizer Inc. (NYSE: PFE - Get Free Report) rose 2.3% during mid-day trading on Monday after the company announced a dividend. The company traded as high as $26.65 and last traded at $26.4470.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
10:01am, Monday, 15'th Dec 2025
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
08:24am, Monday, 15'th Dec 2025
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
08:00am, Monday, 15'th Dec 2025
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research
Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE
05:10am, Monday, 15'th Dec 2025
Cullen Capital Management LLC decreased its holdings in Pfizer Inc. (NYSE: PFE) by 22.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional i
